Roche is staking its claim in the race to develop a BTK inhibitor for multiple sclerosis, with a topline Phase II win showing its candidate reduced brain lesions.
There are no numbers yet — Roche and its subsidiary Genentech are saving those for a medical meeting — but the companies...
